News
VTRS
19.04
-0.86%
-0.17
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
NASDAQ · 1d ago
Viatris commences tender offer to acquire Pacira for $36.50 per share in cash
TipRanks · 1d ago
Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr
Benzinga · 1d ago
Press Release: Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Dow Jones · 1d ago
Press Release: Viatris Announces Commencement of -2-
Dow Jones · 1d ago
Viatris (VTRS) Stock Looks Undervalued With Sales Support Behind It
Simply Wall St · 2d ago
Is Viatris (VTRS) A Bargain After Its FDA Approval Expanded RYZUMVI Use?
Simply Wall St · 3d ago
Earnings Preview: What to Expect From Viatris' Report
Barchart · 4d ago
Will Presbyopia Approval Change Viatris (VTRS) Narrative
Simply Wall St · 4d ago
Viatris Is Maintained at Neutral by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $14
Benzinga · 5d ago
Viatris price target raised to $14 from $13 at Piper Sandler
TipRanks · 5d ago
Weekly Report: what happened at VTRS last week (1019-1023)?
Weekly Report · 5d ago
Notable healthcare headlines for the week: Moderna, Roche, and Abbott Laboratories in focus
Seeking Alpha · 6d ago
Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win
NASDAQ · 10/23 14:53
Viatris Is Maintained at Neutral by JP Morgan
Dow Jones · 10/21 15:30
JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20
Benzinga · 10/21 15:20
Viatris price target raised to $20 from $18 at JPMorgan
TipRanks · 10/21 11:50
What Viatris Holders Bought Into Before An 83% Run
Simply Wall St · 10/20 06:28
Weekly Report: what happened at VTRS last week (1012-1016)?
Weekly Report · 10/19 09:35
More
Webull provides a variety of real-time VTRS stock news. You can receive the latest news about Viatris Inc Ord Shs through multiple platforms. This information may help you make smarter investment decisions.
About VTRS
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.